Practical Considerations for the Use of Clinical Outcome Assessments (COAs) in Pediatric Clinical Research: Examples From Pediatric Gastroenterology
- PMID: 30236008
- DOI: 10.1177/2168479015621601
Practical Considerations for the Use of Clinical Outcome Assessments (COAs) in Pediatric Clinical Research: Examples From Pediatric Gastroenterology
Abstract
Clinical outcome assessments (COAs), including patient-reported outcome (PRO) measures, are routinely used in drug development and other clinical research initiatives to assess the impact of treatment on patient health and well-being. The FDA Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims (2009), the European Medicines Agency's Reflection Paper on the Regulatory Guidance for the Use of Health-Related Quality of Life Measures in the Evaluation of Medicinal Products (2005), and the International Society for Pharmacoeconomics and Outcomes Research PRO Good Research Practices for the Assessment of Children and Adolescence Task Force (2013) outline key considerations and good measurement principles that are relevant to the selection and use of COAs in a pediatric population. However, challenges remain in the appropriate selection and use of COAs to assess treatment benefit in pediatric clinical research. The purpose of this paper is to summarize proceedings from a panel presentation at the Critical Path Institute's 2015 Annual PRO Consortium Workshop. This paper underscores the importance of considering children's specific needs and the numerous challenges faced when developing and implementing well-defined and reliable COAs in pediatric clinical trials evaluating medical products, and describes some approaches to addressing these unique needs and challenges.
Keywords: clinical trial; drug development; functional constipation; gastroesophageal; patient-reported outcome (PRO).
Similar articles
-
Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force.Value Health. 2013 Jun;16(4):461-79. doi: 10.1016/j.jval.2013.04.004. Value Health. 2013. PMID: 23796280
-
Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.Value Health. 2009 Jun;12(4):419-29. doi: 10.1111/j.1524-4733.2008.00470.x. Epub 2008 Nov 11. Value Health. 2009. PMID: 19900250
-
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.Health Qual Life Outcomes. 2006 Oct 11;4:79. doi: 10.1186/1477-7525-4-79. Health Qual Life Outcomes. 2006. PMID: 17034633 Free PMC article.
-
Clinical outcome assessment in clinical trials of chronic pain treatments.Pain Rep. 2021 Jan 21;6(1):e784. doi: 10.1097/PR9.0000000000000784. eCollection 2021 Jan-Feb. Pain Rep. 2021. PMID: 33521482 Free PMC article. Review.
-
Pediatric Crohn Disease Clinical Outcome Assessments and Biomarkers: Current State and Path Forward for Global Collaboration.J Pediatr Gastroenterol Nutr. 2017 Mar;64(3):368-372. doi: 10.1097/MPG.0000000000001284. J Pediatr Gastroenterol Nutr. 2017. PMID: 27253661
Cited by
-
Primary Endpoints in Pediatric Efficacy Trials Submitted to the US FDA.J Clin Pharmacol. 2018 Jul;58(7):885-890. doi: 10.1002/jcph.1109. Epub 2018 Apr 17. J Clin Pharmacol. 2018. PMID: 29663424 Free PMC article.
-
Measuring Health-Related Quality of Life in Pediatric Neurology.J Child Neurol. 2020 Sep;35(10):681-689. doi: 10.1177/0883073820923809. Epub 2020 Jun 4. J Child Neurol. 2020. PMID: 32498657 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
Other Literature Sources